Aflibercept Purification for Binding Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aflibercept formulations have variations in attributes such as Y92L clipping, N68 occupancy, and sialic acid content that affect its binding efficiency to VEGF-A and PlGF, leading to inconsistent therapeutic outcomes in treating conditions like wet age-related macular degeneration and cancer.
Innovation Solution
Developing compositions of aflibercept with controlled levels of Y92L clipping and N68 occupancy, and optimizing sialic acid content through purification processes involving anion exchange chromatography followed by hydrophobic interaction chromatography, which reduces the amount of Y92L clipped species and increases the binding affinity to VEGF-A and PlGF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional purification processes are used to produce aflibercept, then production efficiency is maintained, but attribute variations (Y92L clipping, N68 occupancy, sialic acid content) lead to inconsistent binding efficiency and therapeutic outcomes
Solution Approach 1:
The patent applies parameter changes by systematically controlling and optimizing specific attributes of aflibercept including Y92L clipping levels, N68 occupancy, and sialic acid content. By adjusting purification process parameters to achieve target ranges for these attributes, the patent ensures consistent binding efficiency and therapeutic outcomes while maintaining production reliability.
Solution Approach 2:
The patent implements feedback mechanisms through characterization methods that monitor and measure aflibercept attributes (Y92L clipping, N68 occupancy, sialic acid content) during the purification process. This feedback allows for real-time process adjustment to maintain attribute consistency and ensure reliable binding efficiency throughout production.
2Reliability
If purification processes are extended to control attribute variations, then binding efficiency and therapeutic outcomes are improved, but production time and process complexity increase
Solution Approach 1:
The patent applies preliminary action by incorporating attribute control steps early in the purification process rather than performing extensive characterization and adjustment at later stages. By preliminarily controlling Y92L clipping, N68 occupancy, and sialic acid content during initial purification steps, the patent reduces the need for time-consuming corrective measures later in the production cycle.
Solution Approach 2:
The patent optimizes purification process parameters to achieve attribute control more efficiently. By changing key process parameters (such as chromatography conditions, pH, temperature, and flow rates) to favor the formation of desired aflibercept attributes, the patent reduces the overall time required for purification while maintaining therapeutic outcome consistency.
3Strength
If strict control of Y92L clipping and N68 occupancy is implemented, then binding affinity to VEGF-A and PlGF is enhanced, but manufacturing complexity and process difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the purification process into distinct stages, each targeting specific attributes (Y92L clipping control, N68 occupancy control, and sialic acid content control). This segmentation allows for focused optimization of binding affinity parameters while managing process complexity through modular, manageable steps rather than a single complex process.
Solution Approach 2:
The patent uses parameter changes to simplify the control of binding affinity attributes. By adjusting specific process parameters (chromatography conditions, incubation times, temperature, pH) to optimal values, the patent enhances binding affinity to VEGF-A and PlGF while reducing the overall complexity of the purification process through systematic parameter optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized aflibercept composition demonstrates enhanced binding efficiency to VEGF-A and PlGF, leading to improved therapeutic efficacy in treating ocular and cancer-related conditions by minimizing the impact of attribute variations.
Implementation Method 1
purification processes involving anion exchange chromatography followed by hydrophobic interaction chromatography
Implementation Method 2
purification processes involving anion exchange chromatography followed by hydrophobic interaction chromatography
Implementation Method 3
reduced capillary electrophoresis sodium dodecyl sulfate (rCE-SDS)
Data Source
AI summary
The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.